摘要
目的 观察 p185、nm2 3- H1蛋白及 PCNA在甲状腺良、恶性肿瘤中表达并探讨其临床应用价值。方法 采用免疫组织化学 (SP法 )检测 117例各类甲状腺肿瘤三种蛋白表达状况。结果 p185、nm2 3- H1蛋白及 PCNA在甲状腺癌中表达阳性率分别是 46 .70 % (2 8/ 6 0 )、41.70 % (2 5 / 6 0 )和 90 % (5 4/ 6 0 ) ,在甲状腺良性肿瘤分别是 8.77% (5 /5 7)、2 9.83% (17/ 5 7)和 2 1.0 5 % (12 / 5 7)。甲状腺癌的 PC-NA和 p185共表达率 (4 3.30 % )明显高于甲状腺良性肿瘤(1.75 % ) (P<0 .0 0 1)。结论 PCNA和 p185在甲状腺癌发生发展中具有一定相关性 ,而且在甲状腺癌与甲状腺良性肿瘤的鉴别诊断中可能有重要意义。
Objective To investigate the expression of p185neu、nm23-H1 protein and PCNA in benign and malignant thyroid tumors and to discuss the value of its clinicaluse. Methods In 117 cases of thyroid tumors these 3 proteins were detected by immunohistochemical methods. Results The postive rates for p185neu、nm23-H1 protein and PCNA were 46 70 % (28/60)、41 70 % (25/60) and 90 % (54/60) respectively in thyroid carcinoma and were only 8 77 % (5/57)、29 83 % (12/57) and 21 05 % (12/57) respectively in benign thyroid tumors. The co-expression of p185neu and PCNA was 43 30 % in thyroid carcinoma, significantly higher than that in benign thyroid tumors (1 75 %) ( P <0 001). Conclusion PCNA and p185neu were correlated with the origin and development of thyroid tumors, moreover p185neu and PCNA co-expression is valuable for differentiate benign from malignant thyroid tumos.
出处
《肿瘤》
CAS
CSCD
北大核心
2000年第6期448-449,共2页
Tumor
关键词
甲状腺肿瘤
增殖细胞核抗原
P185
NM23-H1
表达
Thyroid neoplasms
Gene products,p185neu
Gene products,nm23-H1 protein
PCNA
Immunohistochemistry
